Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at UCLA, shared an article by Andres Huertas, et al. on X:
“A trio of radiation oncologists from France, the United States, and Australia asks why there is a desire to deliver SBRT to ultra-central tumors.
Especially when a 3-week hypofractionation (60/15) course seems to be just fine.”
Comment on Wu et al’s article on toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer.
Authors: Andres Huertas, et al.
